Dual-porosity hollow nanoparticles for the immunoprotection and delivery of nonhuman enzymes

Inanc Ortac, Dmitri Simberg, Ya San Yeh, Jian Yang, Bradley Messmer, William C. Trogler, Roger Y. Tsien, Sadik Esener

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Although enzymes of nonhuman origin have been studied for a variety of therapeutic and diagnostic applications, their use has been limited by the immune responses generated against them. The described dual-porosity hollow nanoparticle platform obviates immune attack on nonhuman enzymes paving the way to in vivo applications including enzyme-prodrug therapies and enzymatic depletion of tumor nutrients. This platform is manufactured with a versatile, scalable, and robust fabrication method. It efficiently encapsulates macromolecular cargos filled through mesopores into a hollow interior, shielding them from antibodies and proteases once the mesopores are sealed with nanoporous material. The nanoporous shell allows small molecule diffusion allowing interaction with the large macromolecular payload in the hollow center. The approach has been validated in vivo using l-asparaginase to achieve l-asparagine depletion in the presence of neutralizing antibodies.

Original languageEnglish (US)
Pages (from-to)3023-3032
Number of pages10
JournalNano Letters
Volume14
Issue number6
DOIs
StatePublished - Jun 11 2014
Externally publishedYes

Fingerprint

Porosity
Nanoparticles
enzymes
hollow
delivery
Enzymes
Enzyme Therapy
antibodies
porosity
Antibodies
Asparaginase
nanoparticles
Asparagine
Prodrugs
depletion
platforms
Neutralizing Antibodies
protease
Peptide Hydrolases
nutrients

Keywords

  • enzyme encapsulation
  • immune response
  • Nanomedicine
  • nanoparticles
  • nonhuman enzymes
  • silica

ASJC Scopus subject areas

  • Condensed Matter Physics
  • Bioengineering
  • Chemistry(all)
  • Materials Science(all)
  • Mechanical Engineering
  • Medicine(all)

Cite this

Ortac, I., Simberg, D., Yeh, Y. S., Yang, J., Messmer, B., Trogler, W. C., ... Esener, S. (2014). Dual-porosity hollow nanoparticles for the immunoprotection and delivery of nonhuman enzymes. Nano Letters, 14(6), 3023-3032. https://doi.org/10.1021/nl404360k

Dual-porosity hollow nanoparticles for the immunoprotection and delivery of nonhuman enzymes. / Ortac, Inanc; Simberg, Dmitri; Yeh, Ya San; Yang, Jian; Messmer, Bradley; Trogler, William C.; Tsien, Roger Y.; Esener, Sadik.

In: Nano Letters, Vol. 14, No. 6, 11.06.2014, p. 3023-3032.

Research output: Contribution to journalArticle

Ortac, I, Simberg, D, Yeh, YS, Yang, J, Messmer, B, Trogler, WC, Tsien, RY & Esener, S 2014, 'Dual-porosity hollow nanoparticles for the immunoprotection and delivery of nonhuman enzymes', Nano Letters, vol. 14, no. 6, pp. 3023-3032. https://doi.org/10.1021/nl404360k
Ortac I, Simberg D, Yeh YS, Yang J, Messmer B, Trogler WC et al. Dual-porosity hollow nanoparticles for the immunoprotection and delivery of nonhuman enzymes. Nano Letters. 2014 Jun 11;14(6):3023-3032. https://doi.org/10.1021/nl404360k
Ortac, Inanc ; Simberg, Dmitri ; Yeh, Ya San ; Yang, Jian ; Messmer, Bradley ; Trogler, William C. ; Tsien, Roger Y. ; Esener, Sadik. / Dual-porosity hollow nanoparticles for the immunoprotection and delivery of nonhuman enzymes. In: Nano Letters. 2014 ; Vol. 14, No. 6. pp. 3023-3032.
@article{8fd7a53d800a40d8b58e3ee9c08e9b23,
title = "Dual-porosity hollow nanoparticles for the immunoprotection and delivery of nonhuman enzymes",
abstract = "Although enzymes of nonhuman origin have been studied for a variety of therapeutic and diagnostic applications, their use has been limited by the immune responses generated against them. The described dual-porosity hollow nanoparticle platform obviates immune attack on nonhuman enzymes paving the way to in vivo applications including enzyme-prodrug therapies and enzymatic depletion of tumor nutrients. This platform is manufactured with a versatile, scalable, and robust fabrication method. It efficiently encapsulates macromolecular cargos filled through mesopores into a hollow interior, shielding them from antibodies and proteases once the mesopores are sealed with nanoporous material. The nanoporous shell allows small molecule diffusion allowing interaction with the large macromolecular payload in the hollow center. The approach has been validated in vivo using l-asparaginase to achieve l-asparagine depletion in the presence of neutralizing antibodies.",
keywords = "enzyme encapsulation, immune response, Nanomedicine, nanoparticles, nonhuman enzymes, silica",
author = "Inanc Ortac and Dmitri Simberg and Yeh, {Ya San} and Jian Yang and Bradley Messmer and Trogler, {William C.} and Tsien, {Roger Y.} and Sadik Esener",
year = "2014",
month = "6",
day = "11",
doi = "10.1021/nl404360k",
language = "English (US)",
volume = "14",
pages = "3023--3032",
journal = "Nano Letters",
issn = "1530-6984",
publisher = "American Chemical Society",
number = "6",

}

TY - JOUR

T1 - Dual-porosity hollow nanoparticles for the immunoprotection and delivery of nonhuman enzymes

AU - Ortac, Inanc

AU - Simberg, Dmitri

AU - Yeh, Ya San

AU - Yang, Jian

AU - Messmer, Bradley

AU - Trogler, William C.

AU - Tsien, Roger Y.

AU - Esener, Sadik

PY - 2014/6/11

Y1 - 2014/6/11

N2 - Although enzymes of nonhuman origin have been studied for a variety of therapeutic and diagnostic applications, their use has been limited by the immune responses generated against them. The described dual-porosity hollow nanoparticle platform obviates immune attack on nonhuman enzymes paving the way to in vivo applications including enzyme-prodrug therapies and enzymatic depletion of tumor nutrients. This platform is manufactured with a versatile, scalable, and robust fabrication method. It efficiently encapsulates macromolecular cargos filled through mesopores into a hollow interior, shielding them from antibodies and proteases once the mesopores are sealed with nanoporous material. The nanoporous shell allows small molecule diffusion allowing interaction with the large macromolecular payload in the hollow center. The approach has been validated in vivo using l-asparaginase to achieve l-asparagine depletion in the presence of neutralizing antibodies.

AB - Although enzymes of nonhuman origin have been studied for a variety of therapeutic and diagnostic applications, their use has been limited by the immune responses generated against them. The described dual-porosity hollow nanoparticle platform obviates immune attack on nonhuman enzymes paving the way to in vivo applications including enzyme-prodrug therapies and enzymatic depletion of tumor nutrients. This platform is manufactured with a versatile, scalable, and robust fabrication method. It efficiently encapsulates macromolecular cargos filled through mesopores into a hollow interior, shielding them from antibodies and proteases once the mesopores are sealed with nanoporous material. The nanoporous shell allows small molecule diffusion allowing interaction with the large macromolecular payload in the hollow center. The approach has been validated in vivo using l-asparaginase to achieve l-asparagine depletion in the presence of neutralizing antibodies.

KW - enzyme encapsulation

KW - immune response

KW - Nanomedicine

KW - nanoparticles

KW - nonhuman enzymes

KW - silica

UR - http://www.scopus.com/inward/record.url?scp=84902247305&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902247305&partnerID=8YFLogxK

U2 - 10.1021/nl404360k

DO - 10.1021/nl404360k

M3 - Article

VL - 14

SP - 3023

EP - 3032

JO - Nano Letters

JF - Nano Letters

SN - 1530-6984

IS - 6

ER -